novo nordisk compounded semaglutide asks FDA to prevent compounders from making GLP-1 knockoffs Recent reports link around 10

5.3 Future research directions As the pathogenesis of DCM continues to be explored, future research is likely to focus on several key areas: 5.3.1 Development of precision-targeted drugs Current pharmacological treatments for DCM and its complications largely rely on non-specific approaches, focusing on symptom management rather than addressing the underlying pathological mechanisms

& Weiss, G

Bn c th tham kho mt s cch di y: - n sng: Bn c th n sng r Maca nh 1 loi tri cy bnh thng

By blocking sodium-glucose co-transporter-2 in the kidneys, they promote glucose excretion through urine, effectively lowering blood sugar levels

Figure 2 Baseline values for several biomarkers were significantly different between the mB12/LDFA and placebo groups